Phreesia (NYSE:PHR) Receives “Neutral” Rating from DA Davidson

Phreesia (NYSE:PHR)‘s stock had its “neutral” rating reiterated by DA Davidson in a report released on Friday, Benzinga reports. They currently have a $32.00 price target on the stock. DA Davidson’s target price points to a potential upside of 39.56% from the stock’s previous close.

A number of other research analysts have also recently commented on PHR. KeyCorp decreased their target price on shares of Phreesia from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Thursday, December 7th. Barclays initiated coverage on shares of Phreesia in a report on Wednesday, January 3rd. They issued an “overweight” rating and a $29.00 price objective on the stock. Truist Financial began coverage on Phreesia in a research report on Monday, February 26th. They issued a “buy” rating and a $35.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Friday. Finally, Raymond James reaffirmed an “outperform” rating and issued a $30.00 price objective (up from $25.00) on shares of Phreesia in a research note on Friday. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Phreesia has a consensus rating of “Moderate Buy” and a consensus price target of $32.71.

Phreesia Trading Down 3.5 %

Shares of PHR stock traded down $0.82 on Friday, hitting $22.93. 693,167 shares of the stock traded hands, compared to its average volume of 545,245. Phreesia has a twelve month low of $12.05 and a twelve month high of $36.13. The stock has a market capitalization of $1.28 billion, a PE ratio of -9.10 and a beta of 0.93. The firm’s 50-day moving average price is $25.31 and its two-hundred day moving average price is $20.99. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.02 and a current ratio of 2.02.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.02. Phreesia had a negative net margin of 38.42% and a negative return on equity of 52.97%. The firm had revenue of $95.00 million for the quarter, compared to analyst estimates of $93.52 million. During the same quarter in the previous year, the company earned ($0.72) EPS. The business’s revenue for the quarter was up 24.0% compared to the same quarter last year. As a group, analysts anticipate that Phreesia will post -1.47 EPS for the current year.

Insider Buying and Selling

In other Phreesia news, COO Evan Roberts sold 2,247 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $24.55, for a total transaction of $55,163.85. Following the transaction, the chief operating officer now owns 795,613 shares in the company, valued at approximately $19,532,299.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Chaim Indig sold 3,586 shares of Phreesia stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $24.55, for a total transaction of $88,036.30. Following the completion of the sale, the chief executive officer now directly owns 1,280,410 shares in the company, valued at approximately $31,434,065.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Evan Roberts sold 2,247 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $24.55, for a total value of $55,163.85. Following the sale, the chief operating officer now owns 795,613 shares in the company, valued at $19,532,299.15. The disclosure for this sale can be found here. Insiders sold 9,950 shares of company stock valued at $246,213 over the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Institutional investors and hedge funds have recently made changes to their positions in the business. International Assets Investment Management LLC raised its position in shares of Phreesia by 1,987.3% during the 4th quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock worth $34,000 after purchasing an additional 1,411 shares during the last quarter. Captrust Financial Advisors raised its holdings in shares of Phreesia by 154.6% in the second quarter. Captrust Financial Advisors now owns 1,426 shares of the company’s stock worth $36,000 after acquiring an additional 866 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Phreesia in the first quarter valued at $43,000. State of Wyoming boosted its stake in shares of Phreesia by 34.6% during the second quarter. State of Wyoming now owns 1,918 shares of the company’s stock valued at $59,000 after acquiring an additional 493 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Phreesia by 85.4% during the third quarter. Tower Research Capital LLC TRC now owns 3,137 shares of the company’s stock valued at $80,000 after acquiring an additional 1,445 shares during the last quarter. 94.37% of the stock is currently owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.